CLIA Waiver Sign-Off May Return To FDA – OIVD’s St. Pierre
This article was originally published in The Gray Sheet
HHS may decide by Nov. 1 whether to shift the delegation authority for CLIA waivers to FDA, OIVD Deputy Director for New Device Evaluation Donald St. Pierre stated at the Regulatory Affairs Professionals Society's annual conference in Baltimore Oct. 22
You may also be interested in...
The possibility of recommending a process whereby CLIA waivers can be withdrawn for certain in vitro diagnostic tests will be examined by a workgroup of CDC's Clinical Laboratory Improvement Advisory Committee
The Centers for Medicare & Medicaid Services will have the authority to make the final call on whether products receive CLIA waiver, according to FDAers.
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.